Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer.
Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer. Oncotarget. 2018 Jan 12; 9(4):4375-4384.